Once-daily 5% minoxidil foam for female pattern hair loss

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 interventional trial compares once-daily 5% minoxidil foam to a matching placebo in adult women diagnosed with androgenetic alopecia. The primary outcome is the Target Area Terminal Hair Count (TAHC) to measure change in hair density. Eligible participants have hair loss graded D3–D6 on the Savin scale and must agree to maintain hairstyle and use effective contraception during the trial. The trial is sponsored by Zhejiang Sunshine Mandi Pharmaceutical and conducted at a site in Beijing, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Voluntarily participate in the study and be able to provide a written Informed Consent Form (ICF);
* Female aged ≥ 18 years;
* Investigator-diagnosed androgenetic alopecia;
* Hair loss severity graded D3 to D6 on the Savin scale;
* Willingness to maintain identical hairstyle, hair color, and hair length at each follow-up visit;
* No pregnancy plans during the study and for 3 months post-last dose, with commitment to highly effective contraception. Women of childbearing potential must have negative serum pregnancy test ≤7 days prior to first investigational product administration

Exclusion Criteria:

* Trial participants with known hypersensitivity to minoxidil or any excipient of the investigational product.
* Trial participants with known hair loss disorders other than androgenetic alopecia (AGA)
* Trial participants with any scalp disorder at screening that may interfere with efficacy evaluation, as determined by the investigator.
* Lactating women
* Trial participants with history of hypotension or uncontrolled hypertension
* Trial participants with clinically significant abnormal laboratory findings at screening that may compromise efficacy and safety assessments, as determined by the investigator.
* Trial participants with clinically significant ECG abnormalities at screening
* Trial participants with history of malignancy prior to screening.
* Trial participants known to have conditions or disorders that may affect hair growth or compromise study results.
* Trial participants with history of using systemically administered therapeutic drugs prior to screening that may interfere with efficacy evaluation, etc.
* Trial participants with history of topical minoxidil application to alopecia-affected areas prior to screening.
* Trial participants with no response to prior minoxidil treatment for alopecia
* Trial participants with history of 5α-reductase inhibitor use prior to screening.
* Trial participants with history of spironolactone or cyproterone treatment prior to screening.
* Trial participants with history of autologous platelet-rich plasma (PRP) administration prior to screening.
* Trial participants with history of chemotherapy, cytotoxic agents, scalp radiation, and/or low-level laser therapy (LLLT) or surgical scalp procedures for FAGA prior to screening.
* Trial participants with history of using medical shampoos or solutions containing ingredients or other components that may interfere with efficacy evaluation prior to screening.
* Trial participants planning hair transplantation during the study period, or using hair weaving, non-breathable wigs, or hair bonding during treatment.
* Trial participants in other interventional clinical trials within 3 months before screening (excluding non-interventional studies and screen failures) , or planned concurrent clinical trial enrollment.
* Trial participants with history of major surgery within 3 months before screening or planning major surgery during the study period.
* Trial participants deemed by the investigator to have other conditions that may compromise compliance or render them unsuitable for the study.

Where it's running

• Beijing, China
  Beijing, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PP405 0.05% topically applied gel for adult men with pattern hair loss

  A topical gel called PP405 is being tested in adult men with androgenetic alopecia to see if it can help with hair growth and is safe over a year.

  Recruiting at 34 sites Phase 2/3 Pelage Pharmaceuticals, Inc. · Birmingham, Alabama and 62 other locations · NCT07819435

• EPI-001 for androgenetic alopecia in adults

  This early-phase study tests autologous dermal papilla cell therapy (EPI-001) to see if it is safe and can help hair grow in people with androgenetic alopecia.

  Recruiting Phase 1/2 Epibiotech · Seoul, Seoul · NCT07618195

• JAK2 levels in balding and non-balding scalp before and after topical minoxidil

  This will test whether three months of topical minoxidil changes JAK2 protein levels in the scalps of adults (18–50) with mild to moderate androgenetic alopecia.

  Recruiting Kasr El Aini Hospital · Cairo, Cairo Governorate · NCT07563036

• Secretome versus PRP injections to improve hair density in androgenetic alopecia

  This will try secretome injections versus platelet-rich plasma (PRP) injections to see which more effectively increases hair density and the terminal-to-vellus hair ratio in adults with androgenetic alopecia.

  Recruiting Phase 1/2 PT. Prodia Stem Cell Indonesia · Denpasar, Bali · NCT07429253

• Fractional laser plus exosome vs. laser plus placebo for androgenetic alopecia

  This study tests whether adding a human umbilical cord mesenchymal stem cell exosome solution to fractional laser therapy helps men with androgenetic alopecia grow more hair than laser therapy with a placebo.

  Recruiting Chang Gung Memorial Hospital · Taoyuan, Taoyuan · NCT07248410

• CKD-843 for male pattern baldness: a new treatment in Phase 3

  We’re testing CKD-843 in men aged 18–50 with androgenetic alopecia to see if it helps hair loss over 12 months.

  Recruiting Phase 3 Chong Kun Dang Pharmaceutical · Seoul · NCT06916793

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.